Comparison of Adverse Effect Profiles of Nafcillin and Oxacillin in Pediatric Patients.

Q2 Medicine
Shelby R Warring, Jessica M Biggs, Jill A Morgan, Kristine A Parbuoni
{"title":"Comparison of Adverse Effect Profiles of Nafcillin and Oxacillin in Pediatric Patients.","authors":"Shelby R Warring, Jessica M Biggs, Jill A Morgan, Kristine A Parbuoni","doi":"10.5863/1551-6776-29.6.645","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Data comparing the safety profiles of nafcillin and oxacillin are limited in the pediatric patient setting. This study was conducted to compare adverse effect profiles of nafcillin and oxacillin.</p><p><strong>Methods: </strong>This was a single center retrospective study including patients admitted to a children's hospital who received either nafcillin or oxacillin. Patients were excluded if they were older than 18 years or if therapy duration was less than 48 hours. The primary objective was to compare the cumulative sum of adverse effects of nafcillin to oxacillin, including incidence of hypokalemia, nephrotoxicity, hepatotoxicity, neutropenia, infusion-related reactions, loss of intravenous access, and early discontinuation of therapy. Secondary endpoints included comparison of the incidence of each adverse effect collected.</p><p><strong>Results: </strong>Fifty-three patient encounters (representing 46 patients) were included, with 17 patients receiving nafcillin and 36 patients receiving oxacillin. There was no difference between the cumulative sum of adverse effects for nafcillin (n = 16) and oxacillin (n = 45), p = 1. Acute kidney injury (AKI) occurred with both nafcillin and oxacillin at similar rates (21% vs 30%; p = 0.72), as well as hypokalemia for both nafcillin and oxacillin (50% vs 43%; p = 0.46). All but 1 patient who experienced AKI were receiving other nephrotoxin(s) during therapy. Changes in liver transaminases were not significant for either drug. A significant decline in median absolute neutrophil count was noted from pre to post treatment with oxacillin (8400 to 6000 cells/µL; p = 0.002).</p><p><strong>Conclusions: </strong>Our study found no significant difference in adverse effects of nafcillin and oxacillin. Both treatment groups experienced AKI and hypokalemia. Larger studies are needed to determine if one drug is safer than the other.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"29 6","pages":"645-649"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627572/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5863/1551-6776-29.6.645","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Data comparing the safety profiles of nafcillin and oxacillin are limited in the pediatric patient setting. This study was conducted to compare adverse effect profiles of nafcillin and oxacillin.

Methods: This was a single center retrospective study including patients admitted to a children's hospital who received either nafcillin or oxacillin. Patients were excluded if they were older than 18 years or if therapy duration was less than 48 hours. The primary objective was to compare the cumulative sum of adverse effects of nafcillin to oxacillin, including incidence of hypokalemia, nephrotoxicity, hepatotoxicity, neutropenia, infusion-related reactions, loss of intravenous access, and early discontinuation of therapy. Secondary endpoints included comparison of the incidence of each adverse effect collected.

Results: Fifty-three patient encounters (representing 46 patients) were included, with 17 patients receiving nafcillin and 36 patients receiving oxacillin. There was no difference between the cumulative sum of adverse effects for nafcillin (n = 16) and oxacillin (n = 45), p = 1. Acute kidney injury (AKI) occurred with both nafcillin and oxacillin at similar rates (21% vs 30%; p = 0.72), as well as hypokalemia for both nafcillin and oxacillin (50% vs 43%; p = 0.46). All but 1 patient who experienced AKI were receiving other nephrotoxin(s) during therapy. Changes in liver transaminases were not significant for either drug. A significant decline in median absolute neutrophil count was noted from pre to post treatment with oxacillin (8400 to 6000 cells/µL; p = 0.002).

Conclusions: Our study found no significant difference in adverse effects of nafcillin and oxacillin. Both treatment groups experienced AKI and hypokalemia. Larger studies are needed to determine if one drug is safer than the other.

小儿纳夫西林与奥西林不良反应的比较。
目的:比较萘西林和奥西林在儿科患者中的安全性数据有限。本研究的目的是比较萘西林和奥西林的不良反应。方法:这是一项单中心回顾性研究,包括儿童医院收治的接受萘西林或奥西林治疗的患者。年龄大于18岁或治疗时间小于48小时的患者被排除在外。主要目的是比较nafcillin与oxacillin的累积不良反应,包括低钾血症、肾毒性、肝毒性、中性粒细胞减少、输注相关反应、静脉通路丢失和早期停药的发生率。次要终点包括收集到的每种不良反应发生率的比较。结果:纳入53例患者(46例),其中17例患者接受nafcillin, 36例患者接受oxacillin。nafcillin (n = 16)和oxacillin (n = 45)的不良反应累积总数无差异,p = 1。nafcillin和oxacillin的急性肾损伤(AKI)发生率相似(21% vs 30%;P = 0.72),以及nafcillin和oxacillin的低钾血症(50% vs 43%;P = 0.46)。除1例AKI患者外,所有患者在治疗期间均接受其他肾毒素治疗。两种药物的肝脏转氨酶变化均不显著。从治疗前到治疗后,中位绝对中性粒细胞计数显著下降(8400至6000细胞/µL;P = 0.002)。结论:我们的研究发现萘西林和奥西林的不良反应无显著差异。两个治疗组均出现AKI和低钾血症。需要更大规模的研究来确定一种药物是否比另一种更安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pediatric Pharmacology and Therapeutics
Journal of Pediatric Pharmacology and Therapeutics Medicine-Pediatrics, Perinatology and Child Health
CiteScore
2.40
自引率
0.00%
发文量
90
期刊介绍: The Journal of Pediatric Pharmacology and Therapeutics is the official journal of the Pediatric Pharmacy Advocacy Group. JPPT is a peer-reviewed multi disciplinary journal that is devoted to promoting the safe and effective use of medications in infants and children. To this end, the journal publishes practical information for all practitioners who provide care to pediatric patients. Each issue includes review articles, original clinical investigations, case reports, editorials, and other information relevant to pediatric medication therapy. The Journal focuses all work on issues related to the practice of pediatric pharmacology and therapeutics. The scope of content includes pharmacotherapy, extemporaneous compounding, dosing, methods of medication administration, medication error prevention, and legislative issues. The Journal will contain original research, review articles, short subjects, case reports, clinical investigations, editorials, and news from such organizations as the Pediatric Pharmacy Advocacy Group, the FDA, the American Academy of Pediatrics, the American Society of Health-System Pharmacists, and so on.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信